• Georgia Pioneering First U.S. Distribution Through Independent Pharmacies to Expand Access for Patients 
  

ADEL, Ga., Oct. 24, 2023 /CNW/ --Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, announced the first state inspection for the sale of low-THC medical cannabis products at one of the Company's partnering independent pharmacies in Georgia, the first state in the nation to allow pharmacy sales of medical cannabis.

"This marks a significant milestone in the advancement of access to medical cannabis here in the state of Georgia," said Riverside Pharmacist Jordan Loggins. "This inspection gets us one step closer to putting Trulieve's full selection of low-THC products on our shelves and, ultimately, improving the lives of more of our patients."

Riverside Pharmacy in Gainesville was among the first independent pharmacies in the state to apply for a special permit to dispense low-THC medical cannabis products. On Tuesday, October 24, inspectors with the Georgia Drugs and Narcotics Agency will evaluate Riverside's inventory management operations, security protocols, and adherence to Georgia state regulations, paving the way for the locally owned pharmacy to dispense Trulieve's wide array of low-THC products to its customers.

"We are excited to partner with Riverside and other independent pharmacies throughout the state," said Trulieve Georgia President Dr. Lisa Pinkney. "Having these mutually beneficial relationships with independent pharmacists across the state increases our ability to reach new patients in more communities."

"At Trulieve, we have always been on the forefront of expanding access to medical cannabis and we are proud to be part of Georgia's pioneering efforts in this arena," said Trulieve's Chief Executive Officer Kim Rivers. "Working with independent pharmacies like Riverside offers us a new and innovative channel to educate and serve Georgia patients."

Licensed pharmacies that meet certain requirements can apply through the Georgia Board of Pharmacy for a special permit to sell products derived from low-THC oil, the only form of medical cannabis currently legal in Georgia. Applying pharmacies must submit to inspection by the Georgia Drugs and Narcotics Agency and must also obtain all their low-THC products from companies that are licensed by the Georgia Access to Medical Cannabis Commission ("GMCC"). Trulieve Georgia is one of only two companies currently operating under Class 1 production licenses issued by the GMCC.

Trulieve-partnering pharmacies will offer a wide range of top-quality, low-THC products under Trulieve's Momenta brand including nasal spray, tinctures, capsules, and topicals. Trulieve also offers several free resources on its website to help educate potential patients including its Find a Doctor tool, a free database of authorized physicians offering medical cannabis card evaluations in their area, and information on how to become a registered patient in Georgia.

To learn more about Trulieve Georgia, please visit https://www.trulieve.com/dispensaries/georgia and connect on Instagram,  Facebook, or Twitter.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve   
Instagram: @Trulieve_   
Twitter: @Trulieve 

Investor Contact
Christine Hersey, Vice President of Investor Relations
+1 (424) 202-0210
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Phil Buck, APR, Corporate Communications Manager
+1 (406) 370-6226
This email address is being protected from spambots. You need JavaScript enabled to view it.